|
The United States Renal Data System (USRDS)
|
Resource Development
|
CMS, HRSA
|
NIDDK
|
The United States Renal Data System (USRDS) is a national data system that collects, analyzes, and distributes information about chronic kidney disease and end-stage renal disease (ESRD) in the U.S. The missions of the USRDS are: (1) To characterize the total renal patient population and describe the distribution of patients by socio-demographic variables across treatment modalities; (2) To report on the incidence, prevalence, mortality rates, and trends over time of renal disease by primary diagnosis, treatment modality and other variables; (3) To develop and analyze data on the effect of various modalities of treatment by disease and patient group categories; (4) To identify problems and opportunities for more focused special studies of renal research issues; (5) To conduct cost effectiveness studies and other economic studies of ESRD; and (6) To make the data available to investigators, and by supporting investigator-initiated projects, to conduct biomedical and economic analyses of ESRD patients.
|
|
Therapeutics for Rare and Neglected Diseases (TRND)/FDA Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCATS
|
A group of Therapeutics for Rare and Neglected Diseases (TRND) staff and U.S. Food and Drug Administration (FDA) staff from the Center for Drug Evaluation and Research (CDER) meet on a semi-monthly basis to discuss projects for the TRND program. The purpose of this working group is to discuss the scientific progress on each project toward the eventual goal of an Investigational New Drug Application for each project. Results of experiments are discussed, and TRND staff takes the feedback of FDA/CDER staff into consideration when developing future project plans.
|
|
Tobacco and Nicotine Research Interest Group (TANRIG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, SAMHSA
|
NIDA, NCI, NHGRI, NHLBI, NIAAA, NIAID, NICHD, NIEHS, NIMH, NINR, OD/DPCPSI/OBSSR
|
The Tobacco and Nicotine Research Interest Group (TANRIG) was formed in January 2003 with the goal of increasing collaboration, coordination, and communication of tobacco- and nicotine-related research among National Institutes of Health Institutes and Centers, as well as with other relevant U.S. Department of Health and Human Services agencies.
|
|
Tobacco Regulatory Science Program (TRSP)
|
Research Initiative
|
FDA
|
OD/DPCPSI/ODP, CSR, NCI, NHLBI, NIAAA, NICHD, NIDA, NIDCR, NIEHS, OD/OER
|
Located in the National Institutes of Health (NIH) Office of Disease Prevention, the Tobacco Regulatory Science Program (TRSP) coordinates the trans-NIH collaborative effort with the U.S. Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) to conduct research to support its regulatory activities over tobacco products. Within the framework of the Tobacco Control Act, the NIH and FDA formed an interagency partnership to foster tobacco regulatory research. The NIH has the infrastructure for the solicitation, review, and management of research. The FDA has expertise in tobacco regulatory science and the authority and resources to support research responsive to FDA’s regulatory authority. Support from FDA was used to fund grants and to provide administrative support and oversight to manage Funding Opportunity Announcements (FOA), application review, policy implementation and oversight, and communicating and reporting to a variety of sources.
|
|
Tox21 - Memorandum of Understanding on High Throughput Screening, Toxicity Pathway Profiling, and Biological Interpretation of Findings
|
Research Initiative
|
FDA
|
NIEHS, NCATS
|
This Memorandum of Understanding sets in place mechanisms to strengthen existing collaborations in the research, development, validation, and translation of new and innovative test methods that characterize key steps in toxicity pathways. Central is the exploration of high throughput screening assays and tests using phylogenetically lower animal species as well as high throughput whole genome analytical methods, to evaluate mechanisms of toxicity. Ultimately, the data generated by these new tools is to be provided to risk assessors to use in the protection of human health and the environment. Success is expected to result in test methods for toxicity testing that are more scientifically and economically efficient and models for risk assessment that are more biologically based.
|
|
Toxicology and Risk Assessment Conference (TRAC)
|
Committee, Work group, Advisory group, or Task Force
|
ATSDR
|
NIEHS
|
Toxicology and Risk Assessment Conference (TRAC) is an annual conference planned by multiple Federal Agencies to develop new policy and training modules for risk assessment. The broad base of federal partners includes: ATSDR; NIOSH; USAF 711th HPW/AFRL; USAFCEC; USAPHC; US NAMRU; USEPA-NCEA. In 2015, the planning committee developed a memorandum of understanding to secure agency involvement for providing scientific direction for the conference (i.e. technical input).
|
|
Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
NIAID
|
The presidential declaration issued at the 2009 EU-US summit called for the creation of “a transatlantic task force on urgent antimicrobial resistance issues focused on appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities, prevention of both healthcare- and community-associated drug-resistant infections, and strategies for improving the pipeline of new antimicrobial drugs, which could be better addressed by intensified cooperation between us.” The objectives of the Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) are to increase the mutual understanding of U.S. and EU activities and programs relevant to the antimicrobial resistance issues identified in the declaration to deepen the transatlantic dialogue, provide opportunities to learn from each other, and promote information exchange, coordination, and cooperation.
|
|
Trans-NIH American Indian and Alaska Native Health Communications and Information Workgroup
|
Committee, Work group, Advisory group, or Task Force
|
ACL, IHS
|
NIAMS, CC, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/ORWH, OD/OCPL
|
Formed in 2005, the Trans-NIH AI/AN Health Communications and Information Work Group provides a forum for health education and communications staff from National Institutes of Health (NIH) Institutes, Centers, and Offices to share strategies and effective communication approaches to develop and disseminate health information to American Indian and Alaska Native communities. In partnership with the Indian Health Service (IHS) and the Administration on Aging/Administration for Community Living (AoA/ACL), the Work Group conducts outreach to 1,600 IHS Community Health Representatives (CHRs) and 600 AoA/ACL Title VI grantees nationwide through quarterly e-newsletters featuring NIH health information. The e-newsletter, which replaced quarterly hard-copy mailings, features a wide range of health topics and is distributed to IHS CHRs and AoA/ACL grantees that provide services to Native elders. The purpose of the project is to increase awareness among CHRs and Title VI grantees about the availability of free or low-cost, science-based health information for patients and the general public.
|
|
Trans-NIH Plan for HIV-Related Research
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, HRSA, OS
|
OD/DPCPSI/OAR, CSR, FIC, NCATS, NCCIH, NCI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCR, NIDDK, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI, OD/DPCPSI/ORWH
|
Each scientific area of the strategic plan is developed by Coordinating Committees comprised of representatives from the NIH Institutes and Centers and scientific experts from other agencies, including CDC, HRSA, VA, USAID, DoD, and PEPFAR. These committees assist in developing the annual Trans-NIH Plan for HIV-Related Research to ensure that the AIDS research budget funds the highest priority HIV/AIDS research. The plan 1) frames the development of the NIH AIDS research budget; 2) determines the use of NIH AIDS-designated dollars; 3) tracks and monitors HIV/AIDS research expenditures; and 4) informs the public, the scientific community, Congress, and the AIDS-affected communities about the NIH HIV/AIDS research agenda. The Plan also shapes the NIH investment in HIV/AIDS research.
|
|
Trans-NIH Structural Birth Defects Working Group (SBDWG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NICHD, NEI, NHGRI, NHLBI, NIAAA, NIAMS, NIDCR, NIDDK, NIEHS, NINDS
|
The Trans-NIH SBDWG brings together extramural program officials from NIH components whose missions include research into structural birth defects, with the ultimate goal of facilitating advances in our understanding of the etiology, mechanisms, epidemiology, prevention, and treatment of structural birth defects.
|